Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
VistaGen Therapeutics ( (VTGN) ) has provided an announcement.
On February 13, 2025, Vistagen reported its financial results for the fiscal year 2025 third quarter and provided a corporate update, highlighting advancements in its clinical-stage pipeline. Notably, the company is progressing with Phase 3 trials for fasedienol in the treatment of social anxiety disorder and announced positive results from a Phase 2A trial of PH284 in cancer cachexia. The increased R&D expenses reflect these advancements. Vistagen is optimistic about the transformative potential of its product candidates to address unmet needs in areas like social anxiety, major depressive disorder, and menopausal hot flashes, with 2025 poised as a pivotal year for data readouts and advancements.
More about VistaGen Therapeutics
Headquartered in South San Francisco, CA, Vistagen is a clinical-stage biopharmaceutical company focused on developing and commercializing a diverse pipeline of intranasal therapies called pherines. These therapies aim to leverage nose-to-brain neurocircuitry to address various neurological conditions with innovative, non-systemic treatment options.
YTD Price Performance: -17.47%
Average Trading Volume: 268,142
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $76.29M
Find detailed analytics on VTGN stock on TipRanks’ Stock Analysis page.
